Dr Nijjer — Wegovy & Mounjaro: Weight Loss & Heart Health Preview

Weight & Heart Health

Wegovy & Mounjaro —
A Cardiologist's Guide

The new weight-loss injections are transforming cardiology. Dr Nijjer explains the landmark trial evidence, what these medicines can and cannot do, how to get the best from them, and what every patient needs to know about safety.

12 minute read

Healthy lifestyle and weight management for heart health — Dr Nijjer Harley Street cardiologist

Key Takeaways — Read This First

What You Need to Know About Wegovy & Mounjaro

Wegovy (semaglutide) and Mounjaro (tirzepatide) are once-weekly injections that produce substantial, sustained weight loss — typically 15% and 20–22% of body weight respectively
The SELECT trial (2023) proved for the first time that Wegovy reduces heart attacks and strokes in people with obesity who do not have diabetes — a 20% reduction in major cardiovascular events
These are powerful medicines with real side effects — nausea, vomiting, and gut symptoms are common, especially at the start; rare but serious risks include pancreatitis and gallstones
They are not a cure: weight usually returns if the medication is stopped without lasting lifestyle changes; long-term treatment is likely needed for sustained benefit
Several groups of people should not take these medicines — including those with a personal or family history of medullary thyroid cancer, or who are pregnant
A cardiology consultation can help establish whether these medicines are appropriate for you and monitor your cardiovascular risk factors during treatment

Understanding the New Generation

What Are Wegovy
& Mounjaro?

Wegovy (semaglutide 2.4mg) and Mounjaro (tirzepatide) belong to a new class of medicines that mimic gut hormones to reduce appetite, slow stomach emptying, and fundamentally change how the brain regulates hunger and food reward. They are not appetite suppressants in the old sense — they work at a deeper biological level to reset the body's weight "set point".

Wegovy works by mimicking GLP-1 (glucagon-like peptide-1), a hormone released after eating that signals fullness to the brain. It was originally developed as Ozempic at a lower dose for type 2 diabetes before the higher weight-loss dose was licensed. Mounjaro goes a step further, activating two gut hormone receptors simultaneously — GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) — which produces greater weight loss than GLP-1 activation alone.

Both are given as once-weekly subcutaneous injections using a simple pen device, very similar to an insulin pen. Patients inject themselves in the abdomen, thigh, or upper arm. The dose is started low and increased gradually over several months to minimise side effects — a process known as dose titration.

These are not the diet pills of previous decades. They represent a genuine paradigm shift in the medical treatment of obesity — a disease now recognised by all major medical bodies as a chronic, relapsing condition driven largely by biology rather than willpower.

A word on terminology: You may hear these medicines called "GLP-1 agonists" or "incretin mimetics." You may also see Ozempic mentioned — this is semaglutide at a lower dose (1mg), licensed for diabetes rather than weight loss. Wegovy is the higher-dose (2.4mg) formulation licensed specifically for weight management. They contain the same molecule but at different doses and for different purposes.

The Trial Evidence in Numbers

20% reduction in heart attacks, strokes & cardiovascular death with Wegovy in people without diabetes SELECT trial — NEJM 2023 — 17,604 patients, 3.3 years

22% average body weight loss with Mounjaro (tirzepatide 15mg) — the highest of any approved weight-loss medicine SURMOUNT-1 trial — NEJM 2022 — 2,539 patients, 72 weeks

6mmHg average reduction in systolic blood pressure with semaglutide treatment over one year — independent of weight loss alone SELECT cardiovascular sub-analysis; STEP trial programme

Why a Cardiologist Takes Notice

The Cardiovascular
Evidence Explained

For decades, cardiologists have known that obesity drives cardiovascular disease through raised blood pressure, worsened cholesterol, insulin resistance, and systemic inflammation. What was missing was a medicine that could tackle obesity itself — and prove, in a large randomised trial, that doing so actually prevents heart attacks and strokes.

The SELECT trial, published in the New England Journal of Medicine in November 2023, changed this. It enrolled 17,604 adults with established cardiovascular disease (previous heart attack, stroke, or peripheral arterial disease), a BMI of 27 or above, and no diabetes — and randomised them to Wegovy or placebo on top of standard care. After an average follow-up of 3.3 years, those taking Wegovy had a 20% lower rate of the combined endpoint of cardiovascular death, non-fatal heart attack, and non-fatal stroke.

This is a landmark finding for several reasons. First, the benefit was seen in people without diabetes — a group for whom no weight-loss medicine had previously shown a cardiovascular outcome benefit. Second, the effect was surprisingly large and appeared relatively early in the trial, suggesting mechanisms beyond weight loss itself. Third, the reduction in cardiovascular events exceeded what would be predicted by weight loss alone, pointing to direct beneficial effects of GLP-1 receptor activation on the heart and blood vessels — reducing inflammation, improving endothelial function, and stabilising atherosclerotic plaques.

For Mounjaro, the SURMOUNT-MMO trial reported results in 2025 confirming a significant reduction in major adverse cardiovascular events in people with obesity — adding to the already compelling metabolic and cardiovascular risk factor improvements seen across the SURMOUNT trial programme.

Beyond direct cardiovascular outcomes, both medicines consistently improve blood pressure (typically 5–8 mmHg systolic), reduce triglycerides by 20–30%, improve HDL cholesterol, and reduce markers of inflammation such as hsCRP. In patients with heart failure with preserved ejection fraction (HFpEF), a condition closely linked to obesity, semaglutide has been shown to reduce symptoms and improve quality of life significantly.

From a cardiologist's perspective: These medicines are not just weight-loss drugs that happen to reduce some risk factors. The SELECT trial has established Wegovy as a cardiovascular medicine in its own right — the first of its kind to specifically target obesity as a driver of cardiac events. For patients with established heart disease and obesity, this represents a genuine step change in preventive cardiology.

Comparing the Options

Wegovy vs Mounjaro —
What Is the Difference?

Both medicines work and both produce meaningful weight loss. The differences lie in the mechanism, the average amount of weight lost, the cardiovascular outcome data, and practical considerations. Your cardiologist and prescribing clinician can help determine which is most appropriate.

Cardiovascular Outcome Evidence

Wegovy

Semaglutide 2.4mg — once weekly subcutaneous injection

~15% average total body weight loss at highest dose over 68 weeks
STEP 1 trial, NEJM 2021

Wegovy was the first of this new generation to be licensed for weight management in the UK and has the most extensive cardiovascular outcome evidence. The SELECT trial definitively proved it reduces heart attacks and strokes, making it the preferred choice for patients with established cardiovascular disease.

It is a GLP-1 receptor agonist — mimicking a single gut hormone. The dose is titrated over 16 weeks from 0.25mg to 2.4mg weekly. Most patients find that they feel less hungry, feel full sooner, and have fewer cravings, particularly for calorie-dense and ultra-processed foods.

Licensed in the UK for weight management (BMI ≥30, or ≥27 with weight-related comorbidity)
SELECT trial: 20% reduction in major cardiovascular events — established CVD patients
Also approved for cardiovascular risk reduction specifically (FDA, 2024)
Dose titration: 0.25mg → 0.5mg → 1mg → 1.7mg → 2.4mg over 16–20 weeks
Available on NHS (restricted criteria) and privately through specialist clinics
Same molecule as Ozempic (diabetes) but at a higher dose — they are not interchangeable

Greater Weight Loss

Mounjaro

Tirzepatide 5mg / 10mg / 15mg — once weekly subcutaneous injection

~22% average total body weight loss at 15mg dose over 72 weeks
SURMOUNT-1 trial, NEJM 2022

Mounjaro is the newer and more powerful of the two. By activating both GLP-1 and GIP receptors — a dual mechanism — it produces greater weight loss than semaglutide in head-to-head comparisons. Some patients who have found Wegovy insufficient or intolerable achieve better results with Mounjaro.

The SURMOUNT-MMO trial has now confirmed cardiovascular outcome benefits for tirzepatide in people with obesity, placing it alongside Wegovy as a genuinely cardioprotective treatment rather than simply a metabolic drug. Its dual action may also offer advantages in lipid metabolism and insulin sensitivity.

Licensed in the UK for weight management in adults with BMI ≥30 (or ≥27 with comorbidity)
SURMOUNT-MMO: significant reduction in major cardiovascular events confirmed (2025)
Dose titration: 2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg over 20 weeks
At maximum dose, 1 in 3 patients achieves >25% weight loss — approaching surgical outcomes
Available privately; NHS access for weight management expanding but currently limited
Also licensed as Mounjaro for type 2 diabetes in the UK

Are You a Candidate?

Who Is — and Is Not —
Eligible?

These medicines are not suitable for everyone. Below is a general guide — a prescribing clinician will carry out a full assessment before starting treatment.

Generally Suitable

BMI of 30 or above, regardless of other conditions
BMI of 27–29.9 with at least one weight-related health condition — high blood pressure, type 2 diabetes, high cholesterol, sleep apnoea, or established cardiovascular disease
Established cardiovascular disease (prior heart attack, stroke, or peripheral arterial disease) with BMI ≥27 — especially for Wegovy, given the SELECT trial evidence
Heart failure with preserved ejection fraction (HFpEF) and obesity — strong evidence base for semaglutide
People who have tried lifestyle modification and found it insufficient for meaningful, sustained weight loss
Those committed to long-term treatment and lifestyle change alongside the medication

Not Suitable — Do Not Use

Personal or family history of medullary thyroid carcinoma (MTC) — a specific type of thyroid cancer
Multiple Endocrine Neoplasia syndrome type 2 (MEN2) — a rare hereditary condition
Pregnancy, or planning to become pregnant — women should use effective contraception and discontinue treatment at least 2 months before trying to conceive
Breastfeeding
Personal history of pancreatitis — use with great caution, usually avoided
Type 1 diabetes or diabetic ketoacidosis
Severe eating disorders including anorexia nervosa or bulimia
Severe renal or hepatic impairment (dose adjustment or avoidance required)
Known allergy to any component of the medicine

Your Treatment Journey

What to Expect — Month by Month

Understanding the typical trajectory helps set realistic expectations and prevents stopping treatment prematurely when side effects are at their worst.

Weeks 1–4 — Starting Dose

Side Effects Are Worst Now — Do Not Give Up

The starting dose is intentionally low, but many patients experience nausea, reduced appetite, and occasional vomiting during the first weeks. This is the body adjusting to the hormone signal. Most people find that eating smaller portions, slowly, and avoiding very fatty or very rich food dramatically reduces symptoms. The nausea typically improves significantly by week 4–6. Weight loss in this phase may be modest — typically 1–3% of body weight — as the dose is not yet at its therapeutic level.

Months 1–3 — Dose Titration

Hunger Diminishes, Eating Habits Change

As the dose increases, most patients notice a genuine and sometimes dramatic reduction in hunger — not just less appetite, but a change in the psychological relationship with food. Cravings for sweet and ultra-processed foods often reduce significantly. Weight loss accelerates during this phase, typically reaching 5–8% of body weight by month three. Blood pressure, blood sugar, and triglycerides begin to fall measurably. Blood tests at this stage often show meaningful improvements in cardiovascular risk markers.

Months 3–6 — Approaching Maximum Dose

Significant Weight Loss and CV Benefit Accumulating

By month six at or near the maximum dose, most patients have achieved 10–15% (Wegovy) or 15–20% (Mounjaro) of their starting weight loss. Clothes fit very differently, physical activity becomes easier, and many patients report better sleep, improved mood, and substantially more energy. For patients with hypertension, this is often the point at which medication doses can be reviewed and sometimes reduced under medical supervision.

Months 6–12 — Plateau and Maintenance

Weight Loss Slows — This Is Normal

Most of the total weight loss occurs in the first six to nine months. After this, weight loss slows and eventually plateaus as the body adapts. This is not treatment failure — it is the expected biology of weight regulation. Some patients find they can tolerate dose reductions without regain at this stage. Cardiovascular benefits continue to accumulate even after weight loss plateaus, as the direct effects of GLP-1 receptor activation on the heart and vasculature persist.

Beyond 12 Months — Long-Term Commitment

Stopping Usually Leads to Weight Regain

This is the most important point for patients to understand: when these medicines are stopped, weight typically returns. The STEP 4 trial showed that patients who stopped semaglutide regained two-thirds of their lost weight within one year. This is not a personal failure — it reflects that obesity is a chronic disease requiring ongoing treatment, just as hypertension requires ongoing medication. Long-term treatment is likely needed for sustained cardiovascular benefit. Your prescribing team will help plan a long-term strategy.

Making the Most of Treatment

Tips & Tricks for Best Results

These medicines are highly effective — but they work best as part of a broader commitment to healthier eating and activity. The following practical steps, drawn from clinical experience and trial data, can make a significant difference to both the results you achieve and how well you tolerate the treatment.

Eat Slowly — Always

These medicines slow gastric emptying, so food sits in the stomach longer. Eating quickly leads to overfilling and increases nausea significantly. Put your fork down between bites, chew thoroughly, and aim for meals to last at least 20 minutes. You will feel full much sooner than you used to — stop when you feel satisfied, not when the plate is empty.

Prioritise Protein at Every Meal

When eating less, the risk of losing muscle mass as well as fat is real — and muscles are metabolically important and protect the heart. Aim for 1.2–1.6g of protein per kg of body weight per day. Include lean meat, fish, eggs, dairy, legumes, or protein supplements at every meal. Protein also keeps you fuller for longer and has a high satiety signal, amplifying the medication's effect.

Avoid High-Fat Meals, Especially Early On

Fatty, rich, or fried food is the most reliable trigger for nausea and vomiting with these medicines. During the first four to eight weeks — when nausea is worst — keep meals light, dry, and plain. Bland food (rice, plain chicken, boiled vegetables, crackers) is often best tolerated. As you titrate to higher doses, tolerance usually improves and diet can become more varied.

Stay Well Hydrated

Nausea and reduced appetite can make it easy to forget to drink. Dehydration worsens nausea, causes headaches, and in patients on blood pressure medicines can cause lightheadedness and falls. Sip water steadily throughout the day — aim for 2 litres minimum. Avoid drinking large amounts with meals, as this can increase the sensation of fullness to the point of discomfort.

Inject on the Same Day Each Week

Consistency matters. Choose a day that fits your routine — many people choose Sunday evening or Monday morning — and stick to it. You can inject at any time of day, with or without food. Rotate injection sites (abdomen, thigh, upper arm) each week to prevent localised skin reactions. Store pens in the fridge until first use; thereafter they can be kept at room temperature for up to 28 days.

Add Resistance Exercise

Aerobic exercise is excellent for the heart, but resistance training is particularly important when taking weight-loss medicines to prevent muscle loss. Two to three sessions per week of weight training, resistance bands, or bodyweight exercises such as squats and press-ups will help preserve lean muscle mass, boost metabolism, and improve long-term outcomes. Even light resistance work significantly reduces muscle loss compared to diet alone.

Use the Reduced Appetite Wisely

These medicines give you a window of reduced hunger that makes healthier choices easier than they have ever been before. Use this window deliberately — not just to eat less, but to eat better. This is the ideal time to build a Mediterranean-style eating pattern: more vegetables, legumes, oily fish, and nuts; less ultra-processed food, sugar, and refined carbohydrates. The habits formed during treatment are the ones most likely to persist.

Monitor Your Blood Pressure

Weight loss on these medicines often causes a meaningful fall in blood pressure — which is good news, but can mean your blood pressure medication becomes too strong. If you experience dizziness, lightheadedness on standing, or unusually low readings on a home monitor, contact your GP or cardiologist. Dose reductions in antihypertensive medication may be needed, and should be managed under medical supervision.

Do Not Take More Than Prescribed

Some patients try to accelerate titration to reach the maximum dose faster. This reliably worsens nausea and side effects without improving outcomes. The titration schedule exists because slower increases allow the body to adapt. Missing a dose by several days is common — if you miss a dose by more than five days, skip that dose and take your next one as scheduled. Do not double-dose.

Plan for the Long Term

Have an honest conversation with your prescribing team about what happens if you need to stop — due to cost, availability, pregnancy, or side effects. Discuss whether a lower maintenance dose might be appropriate after the active weight-loss phase. Think of this as a long-term chronic disease treatment, not a course of tablets. The cardiovascular benefits of sustained weight reduction are cumulative and well worth protecting.

What You Need to Know

Side Effects — Honest Information

All medicines have side effects. With Wegovy and Mounjaro, the most common are gastrointestinal and tend to be worst at the start of treatment and after dose increases. Serious side effects are rare but real. Understanding what to expect helps patients manage symptoms rather than stopping treatment prematurely.

Very Common

Affects more than 1 in 10 people — especially at the start and after dose increases

NauseaThe most common side effect. Usually worst in the first 4–8 weeks. Eating slowly, in smaller amounts, reduces it significantly. Typically improves as the body adapts.

VomitingLess common than nausea but affects a significant minority. Almost always triggered by eating too fast, too much, or too fatty a meal. Reduces with dose stabilisation.

DiarrhoeaCommon particularly with Mounjaro. Usually mild and self-limiting. Staying hydrated is important. If persistent, contact your prescribing team.

ConstipationAffects roughly 1 in 5 patients. Slowed gut transit is the mechanism. Increased fluid, fibre, and gentle activity usually resolves it. Laxatives are safe to use.

Reduced appetiteThis is the intended therapeutic effect, but can occasionally lead to insufficient caloric intake. Ensure you are still eating adequate protein and nutrients even when not hungry.

FatigueParticularly during the early weeks. Partly related to reduced caloric intake, partly to the body's metabolic adaptation. Usually improves by month two.

Injection site reactionsMild redness, itching, or bruising at the injection site. Rotating sites weekly reduces this. Persistent or spreading redness should be reviewed.

Monitor Closely

Less common but clinically important — contact your team if these develop

GallstonesRapid weight loss — however achieved — increases the risk of gallstones forming. Symptoms: upper right abdominal pain, especially after fatty meals, sometimes with jaundice. Seek medical review if these occur.

Heart rate increaseBoth medicines can raise resting heart rate by 5–10 beats per minute in some patients. This is usually clinically insignificant but should be monitored in patients with pre-existing arrhythmia.

Low blood pressure symptomsDizziness on standing, lightheadedness, or near-fainting — particularly in patients on blood pressure or diuretic medications. Review antihypertensive doses if weight loss is significant.

Hypoglycaemia (in diabetes patients)These medicines lower blood sugar. If you are also taking insulin or sulphonylureas (e.g., gliclazide), hypoglycaemia risk is real. Dose adjustments of diabetes medicines are almost always needed.

Hair thinningTelogen effluvium — temporary hair shedding — is seen with rapid weight loss of any cause. It typically begins at 3–4 months and resolves spontaneously. Adequate protein intake helps.

Muscle loss (sarcopenia)Losing weight quickly without resistance exercise risks losing significant muscle alongside fat. This is why resistance training and adequate protein are strongly recommended throughout treatment.

Altered taste / food aversionSome patients develop strong aversion to specific foods — particularly meat or very rich food. Usually harmless; ensure nutritional variety is maintained.

Serious — Seek Urgent Help

Rare but important — stop the medicine and seek immediate medical attention

Acute pancreatitisSevere, persistent upper abdominal pain radiating to the back — sometimes with vomiting and fever. Stop the medication and attend A&E or call 999. Requires hospital assessment. Do not restart without specialist review.

Diabetic ketoacidosisRelevant only to patients with type 1 diabetes. Nausea, vomiting, abdominal pain, confusion, fruity breath. Medical emergency — call 999.

Serious allergic reactionRash, swelling of the face, lips, or throat, difficulty breathing — anaphylaxis. Stop immediately and call 999. Extremely rare.

Acute kidney injurySevere vomiting and diarrhoea causing dehydration can precipitate kidney injury. If you cannot keep fluids down for more than 12–24 hours, seek medical help promptly.

Worsening of diabetic eye diseaseRapid improvement in blood sugar control (in diabetic patients) has been associated with a temporary worsening of diabetic retinopathy. Relevant only if you have pre-existing diabetic eye disease — discuss with your ophthalmologist.

Ileus (gut obstruction)Very rare but reported. Persistent severe constipation, inability to pass wind, marked abdominal distension. Seek urgent medical review.

Suicidal ideationThere have been regulatory enquiries into reports of mood changes. The current evidence does not confirm causation — the risk of depression with obesity itself is high. However, report any new or worsening mental health symptoms to your team promptly.

Important Warnings

Contraindications & Special Circumstances

The following are absolute contraindications or important warnings that must be discussed with your prescribing doctor before starting treatment. This is not an exhaustive list — a full medical assessment is essential.

When These Medicines Should Not Be Used

Stop reading if any of these apply and discuss with your doctor before proceeding

Thyroid cancer history: These medicines caused thyroid C-cell tumours in rodent studies at high doses. The relevance to humans is not established but remains uncertain. For this reason, they are absolutely contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC), or with Multiple Endocrine Neoplasia type 2 (MEN2). A family history of thyroid cancer of any type should be disclosed to the prescribing clinician.

Pregnancy and contraception: These medicines must not be taken during pregnancy. They should be stopped at least two months before attempting to conceive. They may impair the absorption of oral contraceptive pills (due to delayed gastric emptying) — additional contraceptive precautions may be needed in the early weeks of treatment. Discuss this with your GP or gynaecologist.

History of pancreatitis: There is a theoretical and possibly real increased risk of pancreatitis with GLP-1 agonists. In patients with previous pancreatitis — however mild — the risk-benefit balance requires careful discussion. These medicines should generally be avoided in this group unless the potential cardiovascular benefit is exceptionally compelling and no alternative exists.

Personal or family history of medullary thyroid carcinoma (MTC)
Multiple Endocrine Neoplasia type 2 (MEN2) syndrome
Pregnancy or breastfeeding
Active or recurrent pancreatitis
Severe gastrointestinal disease (gastroparesis, inflammatory bowel disease)

Interactions with other medicines: Slowed gastric emptying can reduce the absorption rate of other oral medications, including blood pressure tablets, thyroid medication (levothyroxine), and oral contraceptives. These usually remain effective but timing matters — take levothyroxine at least 30–60 minutes before the meal closest to your injection. Warfarin patients should monitor INR more closely during titration as absorption may be affected.

Eating disorders: These medicines significantly reduce appetite and can exacerbate restrictive eating patterns. They should not be prescribed to anyone with an active eating disorder including anorexia, bulimia, or orthorexia without specialist psychiatric supervision. Any history of disordered eating should be disclosed before starting treatment.

The "Ozempic face" and body composition concern: Rapid weight loss causes loss of facial fat volume — visible as hollowing of the cheeks or more prominent features. This is not a medical risk but a cosmetic concern some patients find distressing. Slower titration, adequate protein intake, and resistance exercise help minimise this. Facial volume loss does not recover fully on stopping the medicine.

Type 1 diabetes without specialist supervision
Active eating disorder
Severe renal impairment (eGFR <15) — discuss with nephrologist
Severe hepatic impairment
Known allergy or previous hypersensitivity to the medicine

These medicines are prescription-only. They should never be obtained without a proper medical assessment. Online prescribing without appropriate clinical review misses important contraindications and denies patients the monitoring and support that makes treatment both safe and effective. Please seek advice from a qualified prescribing clinician — your GP, an obesity medicine specialist, or a cardiologist.

Download the Patient Summary

A single-page visual guide to Wegovy & Mounjaro — key facts, benefits, tips, and safety information. Print it or save it to your phone.

Download PDF Guide

Discuss Your Options with
a Specialist Cardiologist

Dr Nijjer assesses cardiovascular risk, reviews whether Wegovy or Mounjaro is appropriate, and monitors blood pressure, cholesterol, and heart function during treatment. Appointments available at 68 Harley Street and across London, often within the same week.

Book a Consultation View All Conditions

Call 0203 983 8001 · jessica@oneheartclinic.com

Medical disclaimer: This page provides general patient education and does not constitute personal medical advice. The information about Wegovy (semaglutide) and Mounjaro (tirzepatide) is based on published clinical trial data and current prescribing guidelines as at May 2026. Individual suitability, dosing, and monitoring requirements vary. These are prescription medicines — always consult a qualified clinician before starting, stopping, or changing any medication. If you experience symptoms that may represent a serious side effect, seek urgent medical attention.